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Aim of the study: Loss of the nuclear lamina protein lamin A/C (LMNA) has been observed in
several human malignancies. The present study aimed to investigate associations between
LMNA expression and clinical outcome in colon cancer patients.
Patients and methods: Clinicopathological data and formalin-fixed paraffin embedded tissues
were collected from 370 stage II and III colon cancer patients. Tissue microarrays were con-
structed, stained for lamin A/C and evaluated microscopically. Microsatellite instability sta-
tus was determined for 318 tumours.
Results: Low levels of LMNA expression were observed in 17.8% of colon tumours, with dis-
ease recurrence occurring in 45.5% of stage II and III colon cancer patients with LMNA-low
expressing tumours compared to 29.6% of patients with LMNA-high expressing tumours
(p = 0.01). For stage II patients, disease recurrence was observed for 35.7% of LMNA-low
compared to 20.3% of LMNA-high expressing tumours (p = 0.03). Microsatellite stable
(MSS) tumours exhibited more frequently low LMNA expression than microsatellite insta-
ble (MSI) tumours (21% versus 9.8%; p = 0.05). Interestingly, disease recurrence among
LMNA-low and LMNA-high expressing MSS tumours varied significantly for stage III
patients who had not received adjuvant chemotherapy (100% versus 37.8%; p < 0.01) while
no such difference was observed for patients who received adjuvant chemotherapy (46.7%
versus 46.0%; p = 0.96).
Conclusion: These data indicate that low expression of LMNA is associated with an
increased disease recurrence in stage II and III colon cancer patients, and suggest that
these patients in particular may benefit from adjuvant chemotherapy.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.fax: +31 20 4443844.
J.A. Fijneman).
the Elsevier OA license.
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Worldwide nearly 1 million people are diagnosed with colo-
rectal cancer each year, half of whom die within 5 years.1
Currently, the primary method for assessing prognosis for
individual patients is the Tumour-Node-Metastasis (TNM)
staging system.2 This classification forms the basis for thera-
peutic decision making, e.g. to decide who benefits from adju-
vant chemotherapy. Adjuvant 5-fluorouracil (5-FU)-based
chemotherapy increases median 5-year survival of stage III
colon cancer patients from 51% to 64%.3 In contrast, no con-
vincing evidence exists for a beneficial effect of postoperative
adjuvant chemotherapy for stage II colon cancer. Neverthe-
less, 20–30% of these patients will develop recurrent disease
after resection of the primary tumour.4,5 Therefore, there is
an evident need to identify stage II CRC patients at high risk
of relapse. Prognostic biomarkers aim to identify such patient
subgroups, to indicate who will benefit from adjuvant
therapy.
Genomic instability is a common feature in colorectal can-
cer pathogenesis. Chromosomal instability is observed in
approximately 85% of colorectal cancers, and is characterised
by gains and losses of relatively large chromosomal seg-
ments.6,7 Microsatellite instability (MSI) is observed in about
15% of sporadic colorectal cancers, and is caused by inactiva-
tion of the DNAmismatch repair system. Importantly, MSI tu-
mours have a favourable outcome, with less lymph node
involvement and reduced occurrence of metastasis compared
to microsatellite stable (MSS) tumours.8,9 As such, MSI status
of primary colon cancers can be used as a prognostic marker
for therapy selection.
The nuclear lamina protein lamin A/C (LMNA) has been
described as another potential prognostic marker for
colorectal cancer.10 The nuclear lamina is composed of
proteins termed lamins that are members of the intermedi-
ate filament family. In humans, one A-type and two B-type
lamin genes have been identified. The lamin A/C gene
encodes two isoforms that are formed by alternative RNA
splicing, the A-type lamins A and C. LMNA germline
mutations are involved in a range of human disorders
collectively referred to as laminopathies, including several
forms of muscular dystrophy, Hutchinson–Gilford progeria
syndrome and Werner’s syndrome.11 Functionally, in addi-
tion to maintaining lamina stability, lamin proteins have also
been associated with cellular mechanisms such as nuclear
pore positioning and function, heterochromatin organisa-
tion, gene expression, cell cycle progression and apoptosis,
stem cell differentiation, DNA replication and repair and
cellular migration.12–18 Signal transduction pathways
influenced by lamins include Wnt- and TGFb-signalling,
which are of particular relevance to colon carcinogenesis.19
Although lamins are commonly expressed by most differen-
tiated somatic cells, LMNA expression may be reduced in
transformed cells as has been demonstrated for several
tumour (sub)types, including colorectal neoplasms.10,20–25
The aim of the present study was to evaluate the protein
expression of LMNA in stage II and III colon cancer tissue
samples to investigate its potential as a prognostic bio-
marker that may aid therapy selection.2. Patients and methods
2.1. Patients
Between 1996 and 2005, 454 patients underwent surgical co-
lon cancer resection at the Kennemer Gasthuis hospital in
Haarlem, The Netherlands, that were classified as stage II
(T3–4, N0, M0) or stage III (T1–4, N1–2, M0) according to the 4th
edition of the TNM-classification system.2 Clinicopathological
patient characteristics were retrieved from clinical and histo-
pathology reports. Disease recurrence was defined as either
local tumour recurrence or distant metastasis, diagnosed by
computed tomography imaging and/or histopathology. Ex-
cluded from this study were patients with a history of colorec-
tal malignancy (n = 12), patients with irradical resections of
the primary tumour (n = 9), and patients who were lost for
follow up (n = 8) or died within 3 months after surgery
(n = 39). The remaining study population consisted of 386
stage II and III colon cancer patients with a median follow
up period of more than 57 months. Collection, storage and
use of tissue and patient data were performed in agreement
with the ‘Code for Proper Secondary Use of Human Tissue
in The Netherlands’.26
2.2. Microsatellite instability analysis
DNA was isolated from formalin-fixed paraffin-embedded
(FFPE) tissues of the colon cancer samples as previously de-
scribed.27 Briefly, haematoxylin–eosin stained sections were
used to select areas with a tumour cell contribution of at least
70%, while adjacent 10 lm serial sections were macro dis-
sected for DNA isolation. DNA samples were analysed for
microsatellite instability using MSI Analysis System, Version
1.2 according to the manufacturer’s instructions (Promega,
Madison, USA). This PCR-based assay uses five mononucleo-
tide repeat markers to determine MSI status. PCR products
were separated by capillary electrophoresis using ABI 3130
DNA sequencer and output data were analysed using the
accompanying package GeneScan 3100 (Applied Biosystems,
Foster City, CA, USA). Tumours were classified as microsatel-
lite instable (MSI) when instability was observed for two or
more markers, otherwise they were considered to be micro-
satellite stable (MSS). MSI status could not be determined
for 15% of tumour samples due to insufficient quality of the
FFPE-derived DNA.
2.3. Tissue Microarrays
Tissue Microarrays (TMAs) were constructed from the 386
stage II and III colon cancer samples.28 Briefly, FFPE colon can-
cer resection specimens were used as donor blocks. Six tissue
cylinders (core biopsies) with a diameter of 0.6 mm were
punched from morphologically representative tissue areas
and transferred into recipient TMA paraffin blocks.
2.4. LMNA immunohistochemical staining
Four micrometre sections were deparaffinised in xylene and
rehydrated through a graded series of alcohol. Endogenous
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peroxide in methanol. Samples were microwave-heated in
10 mM citrate buffer solution (pH 6.0) for antigen retrieval,
and incubated with mouse monoclonal anti-Lamin A and C
(clone Jol2, Abcam Inc., Cambridge, UK) diluted in Antibody
Diluent (Dako Netherlands BV, Heverlee, Belgium) overnight
at 4 C. Staining was visualised using the Powervision+ kit
(Immunologic, Duiven, The Netherlands) and diaminobenzi-
dine as a chromagen, followed by counterstaining with
Mayer’s Haematoxylin. LMNA staining of non-epithelial cells
in the tumour stroma served as an internal positive control.
Overall, LMNA expression could be evaluated for 370 stage II
and III colon cancer patients.
2.5. Evaluation of LMNA expression
Slides were scannedwith a digital Mirax slide Scanner system
(3DHISTECH Ltd., Budapest, Hungary) equipped with a 20·
objective (Carl Zeiss B.V., Sliedrecht, The Netherlands). The
intensity of LMNA nuclear protein expression was scored on
a scale from 0 to 3: 0 = negative; 1 = weak; 2 = moderate;
3 = strong. Examples of LMNA expression are shown in
Fig. 1. Focussing on loss of LMNA expression, the score was
based on the weakest observed staining intensity present in
at least 20% of tumour cells. Using Receiver Operating Charac-
teristics (ROC) curve analysis to determine the optimal cut-off
score,29 patients with score 0 were assigned as ‘LMNA low’Fig. 1 – Examples of immunohistochemical staining for lamin A/
and (D) strong LMNA staining of tumour epithelial cells.and patients with a score P1 as ‘LMNA high’. All samples
were examined and scored independently by two investiga-
tors (E.J.Th. Belt and E.G. van den Berg) without knowledge
of clinicopathological data at the time of assessment. The in-
ter-observer agreement was high (Cohen’s weighted kappa
value Kw = 0.79, with 95% confidence interval (CI): 0.75–0.84),
resulting in undisputed classification into ‘low’ and ‘high’
LMNA levels for 95% of the patients.
2.6. Statistical analysis
Statistical analysis was performed with SPSS 15.0 for
Windows (SPSS Inc., Chicago, Illinois, USA). Differences in
proportions between groups were examined using Pearson’s
Chi-square test or Fisher’s exact test. Survival rates were
displayed using Kaplan–Meier curves and compared using
the log rank test. Multivariate analysis was performed using
backward stepwise logistic regression. All reported p-values
are two-sided with a threshold for significance of 0.05.
3. Results
3.1. Clinicopathological features and disease recurrence
LMNA protein expression was examined for 219 stage II
and 151 stage III colon cancer patients. Their clinico-
pathological characteristics are listed in Table 1. ConformC of colon cancer tissue: (A) negative, (B) weak, (C) moderate,
Table 1 – Clinical and pathological characteristics of study population.
Overall (n = 370) LMNA-low (n = 66) LMNA-high (n = 304) p-Value
Sex
Male 195 (52.7) 39 (59.1) 156 (51.3)
Female 175 (47.3) 27 (40.9) 148 (48.7) NS
Age (years)
Mean (SD) 71.1 (12.0) 69.2 (11.8) 71.5 (12.0)
Median (range) 73.2 (28.5–94.0) 69.2 (38.1–90.0) 73.8 (28.5–94.0) NS
Tumour location
Right sided 162 (43.8) 26 (39.4) 136 (44.7)
Left sided 208 (56.2) 40 (60.6) 168 (55.3) NS
Tumour size (mm)
Mean (SD) 42.2 (19.3) 40.9 (17.4) 42.5 (19.7) NS
Tumour stage
T1 4 (1.1) 1 (1.5) 3 (1.0)
T2 18 (4.9) 5 (7.6) 13 (4.3)
T3 314 (84.9) 55 (83.3) 259 (85.2)
T4 34 (9.2) 5 (7.6) 29 (9.5) NS
Nodal stage
N0 219 (59.2) 42 (63.6) 177 (58.2)
N1 103 (27.8) 18 (27.3) 85 (28.0)
N2 48 (13.0) 6 (9.1) 42 (13.8) NS
No. of nodes examined
Mean (SD) 9.0 (5.2) 8.9 (5.9) 9.0 (5.0) NS
Microsatellite stability status
(Failed samples excluded) (Failed n = 52) (Failed n = 6) (Failed n = 46)
Microsatellite stable (MSS) 257 (80.8) 54 (90.0) 203 (78.7)
Microsatellite instable (MSI) 61 (19.2) 6 (10.0) 55 (21.3) 0.05
Histological grade
Well 23 (6.2) 7 (10.6) 16 (5.3)
Moderate 292 (78.9) 51 (77.3) 241 (79.3)
Poor 55 (14.9) 8 (12.1) 47 (15.5) NS
Mucinous differentiation
Yes 79 (21.4) 8 (12.1) 71 (23.4)
No 291 (78.6) 58 (87.9) 233 (76.6) 0.04
Ulceration
Present 284 (76.8) 50 (75.8) 234 (77.0)
Absent 86 (23.2) 16 (24.2) 70 (23.0) NS
Angioinvasion
Present 73 (19.3) 13 (19.7) 60 (19.7)
Absent 297 (80.3) 53 (80.3) 244 (80.3) NS
Tumour-Node-Metastasis (TNM) and adjuvant chemotherapy (ACT)
Stage II 219 (59.2) 42 (63.6) 177 (58.2)
with ACT 31 (14.2) 3 (7.1) 28 (15.8)
without ACT 188 (85.8) 39 (92.9) 149 (84.2) NS
Stage III 151 (40.8) 24 (36.4) 127 (41.8)
with ACT 81 (53.6) 17 (70.8) 64 (50.4)
without ACT 70 (46.4) 7 (29.2) 63 (49.6) 0.07
Follow up (months)
Median (range) 57.3 (3.5–148.6) 59.4 (9.5–125.5) 57.3 (3.5–148.6) NS
Values in parentheses are percentages unless stated otherwise.
NS: not significant, p-values are all >0.10.
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for stage III patients compared to stage II patients
(p < 0.01; Fig. 2A). MSI status was determined for 318 cases,
and revealed 257 MSS tumours (81%) and 61 MSI tumours
(19%). Although not significant in the present dataset,recurrent disease tended to develop more frequently in pa-
tients with MSS tumours (35.8%) than in patients with MSI
tumours (24.6%; p = 0.10). Likewise, disease-free survival
tended to be worse for MSS patients than for MSI patients
(p = 0.12; Fig. 2B).
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Fig. 2 – Disease free survival curves: (2A) stage II (a; n = 219) and stage III (b; n = 151) colon cancer patients; and (2B)
microsatellite instable (MSI) tumours (a; n = 61) and microsatellite stable (MSS) tumours (b; n = 257).
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Immunohistochemical staining revealed 66 tumours with
low LMNA expression (17.8%) and 304 tumours with high
LMNA expression (82.2%). Disease recurrence occurred more
frequently among patients with LMNA-low expressing tu-
mours (45.5%) compared to LMNA-high expressing tumours
(29.6%; p = 0.01; Table 2). Disease-free survival was signifi-
cantly worse for patients with LMNA-low expressing tu-
mours (p = 0.03; Fig. 3A). Similar percentages of LMNA-low
expressing tumours were observed for stage II and III colon
cancer patients (19.2% versus 15.9%, respectively). When
analysed separately, stage II patients revealed 35.7% recur-
rence in LMNA-low versus 20.3% recurrence in LMNA-highTable 2 – LMNA expression and disease recurrence in total stud
Total LM
All patients (stage II + III, n = 370)
Recurrence 120 (32.4) 3
No recurrence 250 (67.6) 3
Stage II (n = 219)
Recurrence 51 (23.3) 1
No recurrence 168 (76.7) 2
- Without ACT (n = 188)
Recurrence 44 (23.4) 1
No recurrence 144 (76.6) 2
- With ACT (n = 31)
Recurrence 7 (22.6) 2
No recurrence 24 (77.4) 1
Stage III (n = 151)
Recurrence 69 (45.7) 1
No recurrence 82 (54.3) 9
- Without ACT (n = 70)
Recurrence 31 (44.3) 6
No recurrence 39 (55.7) 1
- With ACT (n = 81)
Recurrence 38 (46.9) 9
No recurrence 43 (53.1) 8
Values in parentheses are percentages. ACT: adjuvant chemotherapy.cases (p = 0.03), resulting in a significantly worse disease-free
survival for LMNA-low stage II patients (p = 0.04; Fig. 3B). A
similar trend was observed for stage III colon cancer pa-
tients, which revealed 62.5% recurrence in LMNA-low versus
42.5% recurrence in LMNA-high cases (p = 0.07; and Fig. 3C).
For the subgroup of stage III patients who received chemo-
therapy, no significant differences in recurrence rates were
observed between LMNA-low and -high cases (52.9% and
45.3%, respectively; p = 0.6). However, significant differences
were observed for the subgroup of stage III patients who
did not receive adjuvant chemotherapy, with recurrence
occurring in 85.7% of patients with LMNA-low versus 39.7%
of patients with LMNA-high expressing tumours (p = 0.02;
and Fig. 3D).y population of colon cancer patients.
NA-low LMNA-high p-Value
0 (45.5) 90 (29.6)
6 (54.5) 214 (70.4) 0.01
5 (35.7) 36 (20.3)
7 (64.3) 141 (79.7) 0.03
3 (33.3) 31 (20.8)
6 (66.7) 118 (79.2) 0.10
(66.7) 5 (17.9)
(33.3) 23 (82.1) 0.12
5 (62.5) 54 (42.5)
(37.5) 73 (57.5) 0.07
(85.7) 25 (39.7)
(14.3) 38 (60.3) 0.02
(52.9) 29 (45.3)
(47.1) 35 (54.7) 0.58
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Fig. 3 – Disease free survival curves: (3A) total study population (stage II + III colon cancer patients, n = 370) with LMNA-high
(a; n = 304) and LMNA-low expressing tumours (b; n = 66); (3B) stage II colon cancer patients (n = 219) with LMNA-high
(a; n = 177) and LMNA-low expressing tumours (b; n = 42); (3C) stage III colon cancer patients (n = 151) with LMNA-high
(a; n = 127) and LMNA-low expressing tumours (b; n = 24); and (3D) stage III colon cancer patients stratified for administration
of adjuvant chemotherapy (ACT) and LMNA expression, with high LMNA expression without ACT (a; n = 63), with high LMNA
expression with ACT (b; n = 64), with low LMNA expression with ACT (c; n = 17), and with low LMNA expression without ACT
(d; n = 7). Among patients who did not receive adjuvant chemotherapy, there is a significant difference in disease free survival
between patients with LMNA-high (a) and LMNA-low (d) expressing tumours (log rank 4.8; p = 0.03).
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respect to the effects of two other parameters that are con-
sidered to have prognostic value, i.e. MSI-status and treat-
ment with adjuvant chemotherapy. LMNA-low expressing
tumours were less frequently observed among MSI tumours
(9.8%) than among MSS tumours (21.0%; p = 0.05). Consider-
ing the generally more favourable prognosis of MSI-positive
tumours, the associations of LMNA staining with disease
recurrence were re-evaluated on the subgroup of 257 stage
II and III MSS tumours. Patients with LMNA-low MSS tu-
mours developed recurrence in 48.1% of cases versus
32.5% of patients with LMNA-high MSS tumours (p = 0.03;
Table 3). Likewise, the disease-free survival for patients with
LMNA-low expressing MSS tumours tended to be worse
(p = 0.06; Fig. 4A). For stage II patients with MSS tumours,
recurrence was observed in 39.4% of LMNA-low cases versus
24.1% of LMNA-high cases (p = 0.09). Also, the disease-free
survival tended to be worse for stage II LMNA-low express-ing MSS tumours (p = 0.09; Fig. 4B). For stage III patients
with MSS tumours, recurrence was observed in 61.9% of
LMNA-low cases versus 42.1% of LMNA-high cases
(p = 0.10). There was no significant difference in disease-free
survival between stage III LMNA-low and -high expressing
MSS tumours (p = 0.18; Fig. 4C). However, significant differ-
ences were observed for the subgroup of stage III patients
with MSS tumours who had not received adjuvant chemo-
therapy, with disease recurrence in all cases with LMNA-
low expression (100%) versus in 37.8% of cases with
LMNA-high expression (p < 0.01; Table 3). Such difference
was not observed for stage III patients with MSS tumours
who received adjuvant chemotherapy, with disease recur-
rences in LMNA-low and -high expressing tumours of
46.7% and 46.0%, respectively (p = 0.96). The disease-free
survival curves for stage III patients with MSS tumours
stratified for adjuvant chemotherapy and LMNA expression
are depicted in Fig. 4D. The subgroup of patients with MSI
Table 3 – LMNA expression and disease recurrence in colon cancer patients with microsatellite stable (MSS) tumours.
Total LMNA-low LMNA-high p-Value
All patients MSS (stage II + III, n = 257)
Recurrence 92 (35.8) 26 (48.1) 66 (32.5)
No recurrence 165 (64.2) 28 (51.9) 137 (67.5) 0.03
Stage II MSS (n = 141)
Recurrence 39 (27.7 13 (39.4) 26 (24.2)
No recurrence 102 (72.3) 20 (60.6) 82 (75.9) 0.09
- Without adjuvant CT (n = 119)
Recurrence 33 (27.7) 11 (36.7) 22 (24.7)
No recurrence 86 (72.3) 19 (63.3) 67 (75.3) 0.21
- With adjuvant CT (n = 22)
Recurrence 6 (27.3) 2 (66.7) 4 (21.1)
No recurrence 16 (72.7) 1 (33.3) 15 (78.9) 0.17
Stage III MSS (n = 116)
Recurrence 53 (45.7) 13 (61.9) 40 (42.1)
No recurrence 63 (54.3) 8 (38.1) 55 (57.9) 0.10
- Without adjuvant CT (n = 51)
Recurrence 23 (45.1) 6 (100) 17 (37.8)
No recurrence 28 (54.9) 0 (0) 28 (62.6) <0.01
- With adjuvant CT (n = 65)
Recurrence 30 (46.2) 7 (46.7) 23 (46.0)
No recurrence 35 (53.8) 8 (53.3) 27 (54.0) 0.96
Values in parentheses are percentages. CT: chemotherapy.
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allow meaningful subgroup analysis.
Finally, a multivariate analysis was performed in which
LMNA protein expression was incorporated as one parameter
together with disease stage, age, tumour site, treatment with
adjuvant chemotherapy, MSI status, T-stage, differentiation
grade, and angioinvasive growth of the primary tumour. This
analysis indicated LMNA, disease stage, and angioinvasive
growth as independent risk factors for colon cancer recur-
rence (Table 4).
4. Discussion
The present study evaluated LMNA protein expression in pri-
mary cancer tissue samples from a large cohort of stage II and
III colon cancer patients, to investigate its potential as a prog-
nostic biomarker. Our data demonstrate that reduced LMNA
expression in epithelial cancer cells is associated with an
unfavourable outcome in colon cancer patients (Fig. 3A;
Table 2), and indicate LMNA as an independent risk factor
for disease recurrence. Low expression of LMNA was signifi-
cantly associated with increased disease recurrence within
the group of stage II colon cancer patients, as well as within
the group of stage III colon cancer patients that did not re-
ceive adjuvant chemotherapy (Fig. 3B and D; Table 2). Because
colon cancer patients with MSI tumours are known to have a
better prognosis than patients with MSS tumours, data were
stratified for MSI status.8,9 Although not significant, also with-
in this cohort, patients with MSI tumours tended to have
longer disease free survival rates than patients with MSS tu-
mours (Fig. 2B). Within the group of stage II and III patients
with MSS tumours low levels of LMNA protein expression
were associated with increased disease recurrence (Table 3).
Again, this effect appeared to be much more prominentwithin the group of stage III MSS patients who did not receive
adjuvant chemotherapy compared to the group that did re-
ceive adjuvant chemotherapy (Fig. 4D; Table 3). However, the
size of some of the subgroups used for these analyses became
relatively small, emphasising the need to confirm our findings
in an independent patient cohort. Together, these data sug-
gest that LMNA protein expression can be used as a prognos-
tic factor to predict whether stage II and III colon cancer
patients may benefit from adjuvant chemotherapy.
Previously, one study reported that reduced expression of
LMNA was associated with a more favourable prognosis for
colorectal cancer patients10, a result that seems to be contra-
dictory to our findings. However, there are important differ-
ences between the study cohorts that can explain this
difference. In particular, whereas the present study was re-
stricted to a relatively homogeneous population of stage II
and III colon cancer patients, this other study population also
included stage I patients and rectal cancer patients. Consider-
ing the significant differences in LMNA expression that have
been observed among cancer subtypes, for instance between
small cell lung cancer and non-small cell lung cancer cell
lines, it remains to be resolved whether cancers of the colon
behave similar to or differently from rectal cancers. Also adju-
vant chemotherapy, and in case of rectal cancer neoadjuvant
(chemo-) radiotherapy, may be considerable confounding fac-
tors. In fact, the present study found a significant association
between LMNA expression and survival rates only for stage III
MSS patients who did not receive chemotherapy (Fig. 4D).
Within the group of stage III colon cancer patients who did
receive adjuvant chemotherapy, LMNA is not a risk factor for
disease recurrence (Tables 2 and 3). These data suggest that
LMNA-low expressing tumours are sensitive to (fluorouracil-
based) adjuvant chemotherapy. This hypothesis is supported
by observations that cells with disrupted lamin A function
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Fig. 4 – Disease free survival curves of patients with microsatellite stable (MSS) tumours: (4A) total study population (stage
II + III colon cancer patients, n = 257) with LMNA-high (a; n = 203) and LMNA-low expressing tumours (b; n = 54); (4B) stage II
colon cancer patients (n = 141) with LMNA-high (a; n = 108) and LMNA-low expressing tumours (b; n = 33); (4C) stage III colon
cancer patients (n = 116) with LMNA-high (a; n = 95) and LMNA-low expressing tumours (b; n = 21); (4D) stage III colon cancer
patients stratified for administration of adjuvant chemotherapy (ACT) and LMNA expression, with high LMNA expression
without ACT (a; n = 45), with low LMNA expression with ACT (b; n = 15), with high LMNA expression with ACT (c; n = 50), and
with low LMNA expression without ACT (d; n = 6). Among patients who did not receive adjuvant chemotherapy, there is a
significant difference in disease free survival between patients with LMNA-high (a) and LMNA-low (d) expressing tumours
(log rank 9.7; p < 0.01).
Table 4 – Independent risk factors for colon cancer recurrence (multivariate analysis).
Odds ratio 95% Confidence interval p-Value
Low LMNA expression 2.6 1.4–4.8 0.003
High disease stage (III) 2.6 1.5–4.5 0.001
Angioinvasive growth 3.6 2.0–6.7 <0.001
1844 E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 8 3 7 –1 8 4 5have increased sensitivity to DNA damaging agents such as
ionising radiation and cytotoxic drugs as etoposide and cam-
ptothecin.30 Recently, loss of A-type lamins was shown to in-
duce changes in nuclear distribution of telomeres and to
affect telomere function, thereby inducing chromosomal
instability.14 Interestingly, our data demonstrate that low lev-
els of LMNA expression appear to be more common among
MSS (i.e. predominately chromosomal instable) tumours than
among MSI tumours (p = 0.05), thereby supporting thehypothesis that malfunction of A-type lamins will increase
chromosomal instability and stimulate carcinogenesis.
Increasing genomic instability may enhance tumour progres-
sion, including generation of tumour cell clones that have the
capacity to cause disease recurrence. However, neither the
correlation between loss of LMNA and increases in chromo-
somal instability nor the exact molecular mechanisms that
induce loss of LMNA were investigated in this study. Hence,
additional studies are required to further clarify the effects
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 8 3 7 –1 8 4 5 1845of this and other putative functions of LMNA that may con-
tribute to the pathogenesis of colon cancer.
In conclusion, the present study indicates that LMNA pro-
tein expression has potential as a prognostic biomarker to aid
therapy selection for stage II and III colon cancer patients. In
particular, patients with LMNA-low expressing tumours may
benefit from adjuvant chemotherapy.
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